Open Access

Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations

  • Jhimmy Talbot1,
  • Luiz Alexandre V Magno1, 2,
  • Cinthia VN Santana1,
  • Sandra MB Sousa1,
  • Paulo RS Melo1,
  • Ronan X Correa1,
  • Giuliano Di Pietro1 and
  • Fabrício Rios-Santos1Email author
Contributed equally
BMC Genetics201011:87

DOI: 10.1186/1471-2156-11-87

Received: 9 May 2010

Accepted: 5 October 2010

Published: 5 October 2010

Abstract

Background

N-acetyltransferase type 2 (Nat2) is a phase II drug- metabolizing enzyme that plays a key role in the bioactivation of aromatic and heterocyclic amines. Its relevance in drug metabolism and disease susceptibility remains a central theme for pharmacogenetic research, mainly because of its genetic variability among human populations. In fact, the evolutionary and ethnic-specific SNPs on the NAT2 gene remain a focus for the potential discoveries in personalized drug therapy and genetic markers of diseases. Despite the wide characterization of NAT2 SNPs frequency in established ethnic groups, little data are available for highly admixed populations. In this context, five common NAT2 SNPs (G191A, C481T, G590A, A803G and G857A) were investigated in a highly admixed population comprised of Afro-Brazilians, Whites, and Amerindians in northeastern Brazil. Thus, we sought to determine whether the distribution of NAT2 polymorphism is different among these three ethnic groups.

Results

Overall, there were no statistically significant differences in the distribution of NAT2 polymorphism when Afro-Brazilian and White groups were compared. Even the allele frequency of 191A, relatively common in African descendents, was not different between the Afro-Brazilian and White groups. However, allele and genotype frequencies of G590A were significantly higher in the Amerindian group than either in the Afro-Brazilian or White groups. Interestingly, a haplotype block between G590A and A803G was verified exclusively among Amerindians.

Conclusions

Our results indicate that ethnic admixture might contribute to a particular pattern of genetic diversity in the NAT2 gene and also offer new insights for the investigation of possible new NAT2 gene-environment effects in admixed populations.

Background

Genetic functional polymorphisms of xenobiotic/drug metabolizing enzymes have been associated with pharmacotherapy response differences and disease risk susceptibility [1, 2]. Special emphasis has been placed on a phase II metabolizing enzyme, N-acetyltransferase type 2 (Nat2, EC 2.3.1.5), a milestone in the pharmacogenetics field as one of the first enzymes to be associated as a cause of interindividual variation in drug metabolism [3]. Nat2 catalyzes a transfer of an acetyl group from the cofactor acetyl-coenzyme A (acetyl-CoA) to the amine nitrogen atom of aromatic amines and hydrazines [4]. This enzyme is important in the aromatic and heterocyclic amine conjugating reaction, preventing their metabolic activation into electrophilic intermediates that could initiate DNA damage and potentially induce carcinogenic mutations [5]. Moreover, Nat2 plays a role in the metabolism of different hydrazine and arylamine drugs, such as isoniazid and dapsone, both used in the treatment of Mycobacterium spp. infections [6, 7].

The human NAT2 gene has an intronless open reading frame of 870 base pairs and is primarily expressed in the liver and intestines [810]. It has long been recognized that some single nucleotide polymorphisms (SNPs) in the NAT2 gene may change protein structure and/or stability and segregate in humans into "rapid", "intermediate" and "slow" acetylation phenotypes [11, 12]. The effects of genetic polymorphism in the NAT2 gene on N-acetylation activity led to investigations of NAT2 SNPs as a promising genetic marker for disease risk, drug response therapy and/or adverse reactions to drugs [13]. For example, slow acetylators are at increased risk of peripheral neuropathies and systemic lupus erythematosus due to hepatotoxicity to isoniazid treatment, hypersensibility reactions to sulphonamides and poor tolerance to sulfasalazine and dapsone [14]. Conversely, some authors demonstrated increased risk of myelotoxicity induced by amonafide in rapid acetylators, probably due to the production of higher levels of toxic metabolites from drugs [15].

If genetic factors underlie disease risk, the distribution of susceptibility alleles may be influenced by ethnic diversity [16]. Consistent with this question, several studies have shown that frequencies of NAT2 SNPs differ among established ethnic groups [17]. Although the characterization of the frequency of NAT2 SNPs has been established in some ethnic groups, it is still necessary to investigate the distribution of NAT2 SNPs in populations characterized by a high degree of admixture. Brazilian populations are of particular interest since it was historically originated by Caucasian settlers, descendents of African slaves, and by Amerindians [1820]. In this context, we investigated the frequency of five common NAT2 SNPs (G191A, C481T, G590A, A803G and G857A; G191A) and haplotype structure in a highly admixed population in Northeastern Brazil.

Methods

Subjects

All 183 individuals included in the current study were residents in the Ilhéus area, healthy blood donors at São José Hospital (Ilhéus, Bahia, Brazil) and reported at least 3 familial generations resident in Northeastern Brazil. Volunteers were randomly selected during a 6-month period and classified by self-reported ancestry into Afro-Brazilian, Amerindians (native Brazilian descendents of the Tupinamba tribe) or White. The Human Ethical Committee of Universidade Estadual de Santa Cruz approved the study and all volunteers gave their informed consent.

Sample collection and genotyping

Peripheral blood was collected and genomic DNA isolation was performed from white blood cells using the FlexiGene DNA Kit (Qiagen, Boston, USA). NAT2 genotypes were determined using a modification of a polymerase chain reaction (PCR)-restriction fragment length polymorphisms (RFLP) assay [21]. Genomic DNA (100 ng) amplification was carried out in a 25 μL-reaction volume containing 10 mmolL-1 Tris-HCl (pH 8.3), 50 mmolL-1 KCl, 1.5 mmolL-1 MgCl2, 0.2 mmolL-1 of each deoxynucleotide triphosphate (dNTP), 0.2 μmolL-1 of each oligonucleotide primer (Forward, 5'-GGCTATAAGAACTCTAGGAAC-3' and Reverse, 5'-AAGGGTTTATTTTGTTCCTTATTCTAAAT-3'), and 1.25U of Platinum Taq DNA polymerase (Invitrogen, California, USA). Thermal cycling conditions for the PCR were as follows: 5 min at 94°C, followed by 35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 5 min.

Following amplification, genotyping was performed using a RFLP assay to detect five different NAT2 SNPs: G191A (rs1801279), C481T (rs1799929), G590A (rs1799930), A803G (rs1208) and G857A (rs1799931). In this assay, PCR products (895 bp) were digested separately with Msp I, Kpn I, Taq I, Bam HI (Fermentas, Canada) and Dde I (New England Biolabs, USA) to detect a specific SNP (Table 1). All digestions were performed according to the manufacturer's recommendations. Digested PCR products were separated by electrophoresis on 2% agarose gels (Pronadisa, Madrid, Spain) for Msp I, Kpn I and Bam HI or 10% polyacrylamide gels for Taq I and Dde I (90-100 V for 120 min or 6 hours, respectively) with DNA molecular size markers (Invitrogen, California, USA). The amplified products were visualized with ethidium bromide staining under UV light.
Table 1

NAT2 SNPs used in this study.

SNPs

RFLP Enzyme

Aminoacid Substitution

Enzymatic Activity

Reference

G191A

(rs1801279)

Msp I

Arg64Gln

Reduced

[28, 29]

C481T

(rs1799929)

Kpn I

-

Non-Altered

[28]

G590A

(rs1799930)

Taq I

Arg197Gln

Reduced

[28]

A803G

(rs1208)

Dde I

Lys268Arg

Non-Altered

[26]

G857A*

(rs1799931)

Bam HI

Gly286Gln

Reduced

[28, 30, 31]

These levels are referents to the presence of a single SNP and If there is not anyone SNP in the 2 gene copies. * Substrate dependent

Statistical analysis

Individual marker analysis comparing genetic and allelic frequencies among ethnic groups was performed using χ2 tests. Multiple logistic regression analysis to evaluate ethnic influences on the polymorphism frequency and genetic associations were carried out using the Statistical Package for the Social Sciences v.15.0 (Chicago, IL, USA) and UNPHASED v.3.0.13 [22], respectively. We used default settings of HAPLOVIEW v.4.1 software [23] to evaluate pairwise linkage disequilibrium (LD) between the five SNPs, genotype deviation from Hardy-Weinberg equilibrium (HWE) and for association between haplotypes defined by block in comparison groups [23]. For an accurate type I error, we performed 1,000 permutations in each procedure test to estimate the global significance of the observed differences. The test computes the significance by counting the number of ways the data can be permuted to determine how unusual an observed outcome is. All tests were two-tailed and the p level of significance retained was 0.05.

Results

Allelic and Genotypic Associations

The sample was composed predominantly of Afro-Brazilians (68.31%), Whites (15.3%) and Amerindians (16.39%) (average age 34.3 ± 10.2 yrs, 71% males).

The allele and genotype frequencies of the NAT2 SNPs obtained from all individuals and in separate ethnic groups are summarized in Table 2. 481T was the most frequent allele with 38.79% in the general population (33.9 - 43.3%) whereas the 191A allele was less frequent in the three ethnic groups ranging from 5.0 and 10.7% (8.8% in total). No statistically significant differences were observed in the distribution of NAT2 polymorphisms when comparing Afro-Brazilian and White groups (Table 2). However, allelic and genotypic frequencies of G590A polymorphism were significantly increased in Amerindians when compared with other ethnic groups and remained statistically different after multiple testing corrections (Table 2), and multiple logistic regression analysis (OR = 3.714; 95%CI = 0.28-8.54; p = 0.040) (Table 3). Although homozygous carriers of the A803G mutant allele (GG) were not detected in Afro-Brazilian individuals in this study, this genotype was found in the White and Amerindian descendents with a frequency of 6.1 and 3.4%, respectively. Similarly, homozygous carriers of G857A wild allele (AA) were not found in the Amerindian group.
Table 2

Genotypic and allelic frequency of NAT2 gene in different ethnic groups.

NAT2

SNP

Total

Afro-Brazilians

χ 2

p 1

Whites

χ 2

p 2

Amerindians

χ 2

p 3

G191A

GG

158

104

  

23

  

27

  

GA

22

20

1.075

0.5842

4

1.781

0.4104

3

1.207

0.547

AA

3

1

  

1

  

0

  

G

28

228

0.202

0.6593

50

1.322

0.2471

57

0.942

0.3061

A

338

22

  

6

  

3

  

C481T

CC

72

41

  

11

  

12

  

CT

79

60

2.565

0.2774

15

4.836

0.089

10

2.36

0.3073

TT

31

23

  

2

  

8

  

C

223

142

1.466

0.2221

37

1.079

0.2982

34

0.007

0.9338

T

141

106

  

19

  

26

  

G590A

GG

92

77

  

19

  

10

  

GA

67

46

1.298

0.5224

8

4.312

0.1158

14

9.943

0.0069 b

AA

24

2

  

1

  

6

  

G

251

200

0.005

0.9405

46

4.661

0.0288 a

34

8.4

0.0053 c

A

115

50

  

10

  

26

  

A803G

AA

107

64

  

15

  

17

  

AG

73

61

3.662

0.1603

11

1.333

0.5135

12

0.954

0.6207

GG

3

0

  

2

  

1

  

A

287

189

1.686

0.1836

41

0.117

0.7316

46

0.834

0.3538

G

79

61

  

15

  

14

  

G857A

GG

129

86

  

17

  

24

  

GA

51

33

0.986

0.6108

10

3.391

0.1835

6

3.244

0.1975

AA

3

6

  

1

  

0

  

G

309

205

0.419

0.524

44

2.750

0.0964

54

2.013

0.1373

A

57

45

  

12

  

6

  

p: Genotype and allelic p-value for each marker, respectively. p 1 , p 2 and p 3 : Association between Afro-Brazilians × Whites; Whites × Amerindians and Amerindians × Afro-Brazilians, respectively. a, b and c: p-value adjusted (103 permutations) = 0.06494, 0.006993 and 0.004995, respectively. χ 2 : Chi-square tests. Significant association is indicated in bold.

Table 3

Logistic regression analysis for risk of NAT2 mutant allele carrier among ethnic groups

 

Afro-Brazilians

OR (CI 95%)

p 1

Whites

OR (CI 95%)

p 2

Amerindians

OR (CI 95%)

p 3

191A

1.81 (0.50-6.54)

0.392

1.95 (0.42-9.08)

0.361

0.22 (0.28-1.76)

0.0003

481T

1.35 (0.59-3.06)

0.474

0.97 (0.33-2.78)

0.651

1.50 (0.25-8.71)

0.277

590A

0.33 (0.12-0.95)

0.317

0.27 (0.07-1.03)

0.056

3.71 (0.28-8.54)

0.040

803G

1.52 (0.67-3.47)

0.320

0.97 (0.33-2.82)

0.961

1.02 (0.35-2.98)

0.356

857A

1.73 (0.65-4.60)

0.273

2.56 (0.77-8.51)

0.126

0.39 (0.05-2.89)

0.003

Reference group is G191, C481, G590, A803 and G857, respectively. Odds Ratio (OR) and 95% Confidence Interval (CI) for each reference allele compared are shown. p : p-value. p 1 , p 2 and p 3 . Association between Afro-Brazilians × Whites; Whites × Amerindians and Amerindians × Afro-Brazilians, respectively. Significant association is indicated in bold.

Haplotypic Associations

The sample was in Hardy-Weinberg equilibrium (p > 0.05) for the five SNPs (Table 4), as well as separately by ethnicity (data not shown). NAT2 SNP combinations were inferred from haplotype data. Linkage disequilibrium (LD) analysis in the general population revealed that the five common NAT2 SNPs had the weak D' as well as some low r2 values. Haplotype blocks were constructed if D' between SNPs was 1.0. Using this criterion, significant differences in haplotype structure among the ethnic groups were observed (Figure 1).
Table 4

NAT2 haplotypes frequency in Brazilian ethnic groups.

Haplotype

SNPs (HWpval)

Haplotypes (n)

 

C.N.

G191A

(0.348)

C481T

(0.613)

G590A

(1.0)

A803G

(0.303)

G857A

(0.524)

Total

Afro-Brazilians

Whites

Amerindians

A

(NAT2*4)

G

C

G

A

G

45

33

9

6

B

(NAT2*C)

G

T

G

G

G

35

6

4

3

C*

(NAT2*6A/*6B)

G

C

A

A

G

23

3

1

7

D

(NAT2*11A/*11B)

G

T

G

A

G

23

5

2

2

E

(NAT2*6I/6J)

G

C

A

A

A

11

2

1

-

F

(NAT2*7A/*7B)

G

C

G

A

A

9

1

3

-

G

(NAT2*14A/*14B/*14H)

A

C

G

A

G

8

1

1

-

H

(NAT2*12)

G

C

G

G

G

6

1

1

-

I**

(NAT2*6E)

G

T

A

A

G

5

-

-

3

J

(n.ds.)

G

T

G

A

A

4

1

-

0

K

(NAT2*12C+857A)

G

T

G

G

A

4

1

-

1

L

(NAT2*14C/*14I)

A

T

G

A

G

3

-

1

-

Slow Acetylator Haplotype

A

N

A

N

N

50

29+

6+

11+

HWpval: Hardy-Weinberg equilibrium p-value for the whole sample. * and ** significant difference in frequency between Amerindians and Afro-Brazilians (χ 2 : 6.517; p = 0.0107 and χ 2 : 5.539; p = 0.0186, respectively). C, E, G, I and L are slow acetylator haplotypes and are indicated in bold. '-': Absent or with frequency < 1%. 'N': any nucleotide. '+': haplotypes with frequencies < 1% are included. C.N.: Consensus Human Arylamine N-Acetyltransferase Gene Nomenclature -http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-acetyltransferase-gene-nomenclature; (n.d.s): SNP combination not described

https://static-content.springer.com/image/art%3A10.1186%2F1471-2156-11-87/MediaObjects/12863_2010_Article_834_Fig1_HTML.jpg
Figure 1

LD block structure across NAT2 gene. The upper panel shows the location of 5 polymorphisms in NAT2 gene and lower panel shows the output of Haploview. LD plot where in each square (with D' values written within the box) represent a pairwise linkage disequilibrium relationship between the two SNPs. Squares indicate statistically significant LD between the pair of SNPs as measured by the D' statistic. Darker colours of grey indicate higher values of D', up to a maximum of 1 and white squares indicate pairwise D' values of < 1 with no statistically significant evidence of LD. The blocks generated under confidence interval algorithm of Haploview are marked. A: Afro-Brazilians, B: Whites and C: Amerindians.

Additionally to the haplotype analysis according to LD pattern, another haplotype construction based on acetylator phenotype was performed using the most common NAT2 slow SNPs. Thus, this approach estimates a minimum percentage of slow acetylators and avoids misclassification of NAT2 haplotypes in accordance with official nomenclature. The G191A SNP, which leads to an amino acid change in position 64 of the Nat2 protein, produces an enzyme with reduced acetylation capacity [24, 25]. The same functional phenomenon occurs with the G590A allele. In this context, we estimated that any haplotype comprising at least one of these alleles, 191A and 590A, should be theoretically treated as a slow acetylator. It is worthwhile to observe that the slow acetylator haplotypes are underestimated, since the 857A allele may also generate the slow acetylator phenotype (NAT2*7A and NAT2*7B) [26].

Using this criterion, the haplotype distribution is demonstrated in Table 4. For practical purposes, the haplotype distribution was labelled from A to L in a sliding scale, correspondent to and in accordance with the human NAT2 nomenclature. Five slow acetylator haplotypes were found (C, E, I, J, and L), which were higher in Amerindians (44.9%) than in Afro-Brazilians and Whites (22.9% and 25.8%, respectively) (Table 4). Interestingly, we found some haplotypes in Amerindians that were not found in the other groups (data not shown). The most frequent haplotype among Afro-Brazilians and Whites was "A" (26.1 and 35.3%, respectively), whereas C was the most frequent haplotype among Amerindians (28.6%). Among all haplotypes, only the distribution of "C" and "I" was statistically different between Amerindians and Afro-Brazilians (p = 0.0107 and p = 0.0186, respectively) (Table 4). These two haplotypes are correspondent to NAT2*6 haplotype subgroups, ("C" = NAT2*6B; "I" = NAT2 *6E).

Discussion

Ethnicity is an important variable that influences an individual's health in several ways, in particular increasing risks for the development of chronic diseases and unresponsiveness or adverse reactions to drug treatment [27]. The influence of the ethnic component in the distribution of NAT2 genetic polymorphism is well established. An example is the ethnic-specific 191A allele, mainly identified in Africans (7-20%) and with lower frequencies in Euro-Caucasian groups (less than 2%) [2831]. Another example is the 857A allele, mainly identified in eastern Asians [32].

Following our initial purpose of investigating the frequency of NAT2 SNPs in a Brazilian admixed population, the five most common NAT2 SNPs known from published research were selected. Except for C481T SNP, which does not alter the Nat2 enzymatic function, the other four SNPs are associated with slow acetylator status and had high frequencies in our whole sample as well as among ethnic groups (Table 1 and 2). Although the 191A allele has been described as relatively common in African populations but not in Caucasians, no significant difference was observed between both groups in this study (Table 2). Similar results were obtained for G590A. The ethnic similarity in the distribution of NAT2 SNPs observed in this study could be due to the high degree of admixture between Afro-descendents and Euro-Caucasian groups (mainly Portuguese settlers) that has occurred in Brazil over the centuries since colonization [33]. However, the bias from the self-reported ancestry classification method can not be totally excluded.

Interestingly, meaningful results from the distribution of NAT2 alleles in Amerindian descendents were observed. The 590A allele was significantly more frequent in Amerindians (42.5%) than in White or Afro-Brazilian descendents (19.4% and 20.0%, respectively), even after permutation tests to decrease the risk of a type I error (Table 2). Multiple logistic regression analysis confirmed that Amerindians have the highest frequency of the 590A allele with OR (odds ratio) of 3.714 (95% confidence interval - CI = 0.284-8.545; p = 0.040) (Table 3). Significant difference in the distribution of the 191A allele between Amerindians and other groups was revealed by multiple logistic regression analysis, but not in UNPHASED association. The difference in results may be attributed to the small sample size of 191A carriers among Amerindians. Moreover, the frequency of the 590A allele in Amerindians is higher than what has been reported in studies with Amerindians from Panama (0% and 3.7% in Ngawbe and Embera Amerindians, respectively) [17, 34]. Such unexpected frequency may have originated by phylogeographical differences among Amerindians populations in South-America, miscegenation, and genetic drift.

Despite Fuselli et al. (2007) having found that the NAT2 variants are homogeneously distributed across native populations, the Amerindian sample studied here showed a lower frequency of the 857A allele (10.3%; OR = 0.391; CI= 0.053-2.898; p= 0.003) than those observed in two other Amerindians groups (23.3% and 22.8%) [35] (Table 3). To date, the frequency of the 857A allele observed in this study is similar to Asian and Central America Amerindian populations [17], which corroborates the hypothesis that native Americans descend from people who migrated from Siberia thousands of years ago and therefore share their genetic background [36, 37].

To elicit further information about the relationship of SNPs, a haplotype analysis was performed. Although previous studies have shown the efficiency of the PHASE method, we relied on the work of Sabbagh and Darlu (2005), which shows the effectiveness of the EM method for NAT2 haplotype reconstruction and suggests that there is no impact on phenotype prediction compared to results given by PHASE analysis [38]. We observed significant differences in the haplotype structure and frequency among the descendents of the three ethnic groups (Figure 1 and Table 4). Using haplotype analysis based on LD data, a haplotype block between G590A-A803G (Block 1; Figure 1C) was detected in Amerindians but was not found in the other two ethnic groups. This result may help to explain the highest frequency of slow acetylation haplotypes in Amerindians (Table 4). Consistent with the hypothesis that Amerindians may not be under a high selective pressure for fast metabolism, we have previously reported different distribution patterns of GSTP1 low activity polymorphism in this same Amerindian population [39]. Different distributions found in Amerindians, when compared with other groups, may be attributed to their low degree of admixture despite the high degree of miscegenation in the whole population. This occurs for historical reasons related to the particular way Brazil was colonized. In this way, the Amerindian group still maintains its socio-economic distinction that contributes to low degrees of admixture.

Due to our limited sample size, we suggest a careful matching of ethnicity for future larger genetic investigations. Except among the Amerindian descendents, our results suggest that self reported ethnicity might not have significant effects on the distribution of these NAT2 genetic variants studied in the Brazilian population. This data is relevant due to the classic role of Nat2 on isoniazid metabolism in tuberculosis treatment, which still remains an important problem of public health. In fact, several reports indicate that the acetylator status is associated with drug-induced hepatitis and Mycobacterium-resistance [40, 41]. Furthermore, as observed in other phase II metabolizing enzyme polymorphisms, NAT2 genetic variants have been used as a genetic marker in different diseases like bladder and colon-rectal cancers (fast acetylator and slow acetylator, respectively) [42, 43].

Conclusions

Information gathered on the distribution of genetic polymorphism in populations of different ethnic origins remains essential to understand the interethnic differences in drug disposition and disease risk. This study demonstrates that common distributions of NAT2 SNPs are related with ethnic background in a Brazilian admixed population. Hereafter, DNA sequencing for the entire intron-exon organization of the NAT2 gene will provide more detailed information about genetic diversity and structure in this population. All these findings offer new insights for the investigation of possible non-described NAT2 gene-environment effects in admixed populations.

Notes

Declarations

Acknowledgements

The authors would like to thank Naide Silveira de Souza for helping with the samples and J. Neil Simonsen (Public Health Agency of Canada) for reviewing the manuscript, and Conselho Nacional de Desenvolvimento Científico e Tecnologico (CNPq) and Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB) for financial support.

Authors’ Affiliations

(1)
Laboratório de Farmacogenômica e Epidemiologia Molecular (LAFEM), Universidade Estadual de Santa Cruz
(2)
INCT de Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais

References

  1. Nebert DW: Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?. Am J Hum Genet. 1997, 60: 265-271.PubMed CentralPubMed
  2. Wilkinson GR: Drug metabolism and variability among patients in drug response. N Engl J Med. 2005, 352: 2211-2221. 10.1056/NEJMra032424.View ArticlePubMed
  3. Meyer UA: Polymorphism of human acetyltransferases. Environ Health Prospect. 1994, 102 (Suppl 6): 213-216. 10.2307/3432181.View Article
  4. Riddle B, Jencks WP: Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituent on the rate. J Biol Chem. 1971, 246: 3250-3258.PubMed
  5. Hein DW: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002, 506-507: 65-77.View ArticlePubMed
  6. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 2000, 4: 256-261.PubMed
  7. Palamanda JR, Hickman D, Ward A, Sim E, Romkes-Sparks M, Unadkat JD: Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with ant opportunistic infection drugs. Drug Metab Dispos. 1995, 23: 473-477.PubMed
  8. Blum M, Grant DM, McBride W, Heim M, Meyer UA: Human N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol. 1990, 9: 193-203. 10.1089/dna.1990.9.193.View ArticlePubMed
  9. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, Payton M, Unadkat JD, Sim E: Expression of arylamine N-acetyltransferase in human intestine. Gut. 1998, 42: 402-409. 10.1136/gut.42.3.402.PubMed CentralView ArticlePubMed
  10. Windmill KF, McKinnon RA, Zhu XY, Gaedigk A, Grant DM, McManus ME: The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res. 1997, 376: 153-160.View ArticlePubMed
  11. Evans DA, Manley KA, Mc KV: Genetic control of isoniazid metabolism in man. Br Med J. 1960, 2: 485-491. 10.1136/bmj.2.5197.485.PubMed CentralView ArticlePubMed
  12. Boukouvala S, Sim E: Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts. Basic Clin Pharmacol Toxicol. 2005, 96: 343-351. 10.1111/j.1742-7843.2005.pto_02.x.View ArticlePubMed
  13. Furet Y, Bechtel Y, Le Guellec C, Bechtel PR, Autret-Leca E, Paintaud G: Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. Therapy. 2002, 57: 427-431.
  14. Spielberg SP: N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm. 1996, 24: 509-519. 10.1007/BF02353477.View ArticlePubMed
  15. Norton JT, Witschi MA, Luong L, Kawamura A, Ghosh S, Stack MS, Sim E, Avram MJ, Appella DH, Huang S: Synthesis and anticancer activities of 6-amino amonafide derivatives. Anticancer Drugs. 2008, 19: 23-36. 10.1097/CAD.0b013e3282f00e17.View ArticlePubMed
  16. Wood AJ: Racial differences in the response to drugs-pointers to genetic differences. N Engl J Med. 2001, 344: 1394-1396. 10.1056/NEJM200105033441811.View ArticlePubMed
  17. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008, 9: 21-10.1186/1471-2156-9-21.PubMed CentralView ArticlePubMed
  18. Alves-Silva J, da Silva Santos M, Guimarães PE, Ferreira AC, Bandelt HJ, Pena SD, Prado VF: The ancestry of Brazilian mtDNA lineages. Am J Hum Genet. 2000, 67: 444-461. 10.1086/303004.PubMed CentralView ArticlePubMed
  19. Carvalho-Silva DR, Santos FR, Rocha J, Pena SD: The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet. 2001, 68: 281-286. 10.1086/316931.PubMed CentralView ArticlePubMed
  20. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA. 2003, 100: 177-182. 10.1073/pnas.0126614100.PubMed CentralView ArticlePubMed
  21. Doll MA, Fretland AJ, Deitz AC, Hein DW: Determination of Human NAT2 Acetylator Genotype by Restriction Fragment-Length Polymorphism and Allele-Specific Amplification. Anal Biochem. 1995, 231: 413-420. 10.1006/abio.1995.9978.View ArticlePubMed
  22. Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol. 2003, 25: 115-121. 10.1002/gepi.10252.View ArticlePubMed
  23. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.View ArticlePubMed
  24. Rodrigues-Lima F, et al: 3 D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem Biophys Res Commun. 2003, 291: 116-123. 10.1006/bbrc.2002.6414.View Article
  25. Walraven JM, Zang Y, Trent JO, Hein DW: Structure/function evaluations of single nucleotide polymorphisms in human n-acetyltransferase 2. Curr Drug Metab. 2008, 9: 471-486. 10.2174/138920008784892065.PubMed CentralView ArticlePubMed
  26. Zang Y, Doll MA, Zhao S, States JC, Hein DW: Functional characterization of single nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis. 2007, 28: 1665-1671. 10.1093/carcin/bgm085.PubMed CentralView ArticlePubMed
  27. Au WW, Sierra-Torres CH, Cajas-Salazar N, Salama SA: Inheritance of polymorphic metabolizing genes on environmental disease and quality of life. Mutat Res. 1999, 428: 131-140.View ArticlePubMed
  28. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM: Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics. 1996, 6: 177-185. 10.1097/00008571-199604000-00004.View ArticlePubMed
  29. Patin E, Harmant C, Kidd KK, Kidd J, Froment A, Mehdi SQ, Sica L, Heyer E, Quintana-Murci L: Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat. 2006, 27: 720-10.1002/humu.9438.View ArticlePubMed
  30. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995, 57: 581-592.PubMed CentralView ArticlePubMed
  31. Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J: Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics. 1996, 6: 423-428. 10.1097/00008571-199610000-00006.View ArticlePubMed
  32. Lin HJ, Han CY, Lin BK, Hardy S: Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet. 1993, 52: 827-834.PubMed CentralPubMed
  33. Teixeira RL, Miranda AB, Pacheco AG, Lopes MQ, Fonseca-Costa J, Rabahi MF, Melo HM, Kritski AL, Mello FC, Suffys PN, Santos AR: Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat Res. 2007, 624: 31-40.View ArticlePubMed
  34. Jorge-Nebert LF, Eichelbaum M, Griese EU, Inaba T, Arias TD: Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics. 2002, 12: 39-48. 10.1097/00008571-200201000-00006.View ArticlePubMed
  35. Fuselli S, Gilman RH, Chanock SJ, Bonatto SL, De Stefano G, Evans CA, Labuda D, Luiselli D, Salzano FM, Soto G, Vallejo G, Sajantila A, Pettener D, Tarazona-Santos E: Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J. 2007, 7: 144-152. 10.1038/sj.tpj.6500407.PubMed CentralView ArticlePubMed
  36. Santos FR, Pandya A, Tyler-Smith C, Pena SD, Schanfield M, Leonard WR, Osipova L, Crawford MH, Mitchell RJ: The central Siberian origin for native American Y chromosomes. Am J Hum Genet. 1999, 64: 619-628. 10.1086/302242.PubMed CentralView ArticlePubMed
  37. Lell JT, Sukernik RI, Starikovskaya YB, Su B, Jin L, Schurr TG, Underhill PA, Wallace DC: The dual origin and Siberian affinities of Native American Y chromosomes. Am J Hum Genet. 2002, 70: 192-206. 10.1086/338457.PubMed CentralView ArticlePubMed
  38. Sabbagh A, Darlu P: Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genet. 2005, 6: 30-10.1186/1471-2156-6-30.PubMed CentralView ArticlePubMed
  39. Magno LA, Talbot J, Talbot T, Borges Santos AM, Souza RP, Marin LJ, Moreli ML, de Melo PR, Correa RX, Rios Santos F, Di Pietro G: Glutathione s-transferase variants in a brazilian population. Pharmacology. 2009, 83: 231-236. 10.1159/000205823.View ArticlePubMed
  40. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, Santos AR, Teixeira RL, Gregianini TS, Hutz MH, Rossetti ML, Zaha A: Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol. 2008, 64: 673-681. 10.1007/s00228-008-0484-8.View ArticlePubMed
  41. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 2000, 4: 256-261.PubMed
  42. Agundez JA: Polymorphisms of human n-acetyltransferases and cancer risk. Curr Drug Metab. 2008, 9: 520-531. 10.2174/138920008784892083.View ArticlePubMed
  43. Di Pietro G, Magno LA, Rios-Santos F: Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol. 2010, 6: 153-170. 10.1517/17425250903427980.View ArticlePubMed

Copyright

© Talbot et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement